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Abstract: Cardiac arrest is defined as cessation of cardiac mechanical activity. Cardiopulmonary resuscitation (CPR) is an attempt to
restore spontaneous circulation through several maneuvers and techniques. Although the two interventions, which are competent
basic life support and prompt defibrillation, improve the survival rate, several adjuvant cardiac medication drugs are advocated to
treat cardiac arrest during advanced cardiac life support. Since the introduction of modern CPR there have been many advances in
the field of pharmacotherapy in CPR. Therefore, we aimed to summarise the cardiac medication drugs used for patients in ventricular
fibrillation (VF) or pulseless ventricular tachycardia (VT) or non VF/VT in the practice of advanced cardiac life support. Towards
achieving this aim, the effects and practical issues related to vasopressors, antiarrythmic agents and, others such as sodium
bicarbonate, calcium, magnesium and atropine will be addressed in the scope of the recent updates in the literature.
Key Words: Advanced cardiac life support, Cardiopulmonary resuscitation (CPR), Drug therapy.

Introduction
Cardiac arrest is defined as cessation of cardiac
mechanical activity. It is a clinical diagnosis, confirmed by
unresponsiveness, absence of detectable pulse and apnea
or agonal respirations. Cardiopulmonary resuscitation
(CPR) is an attempt to restore spontaneous circulation
through a broad range of maneuvers and techniques.
Within 15 seconds of cardiac arrest, the patient loses
consciousness, electroencephalogram becomes flat after
30 seconds, pupils dilate fully after 60 seconds and
cerebral damage takes place within 90-300 seconds.
Therefore, it is essential to act immediately as reversible
damage can occur in a short time (1).
The range of activities and skills during Basic life
support (BLS) has been expanded to include automated
external defibrillators (AED) in addition to initial airway
assessment, rescue breathing by small volumes of expired
air ventilation and chest compressions. Uniform
compression-ventilation ratio of 15:2 has been adopted
for single as well as two rescues. AED have been made
available to reduce time lapse in defibrillation.
Defibrillators with biphasic current are also being used
with several advantages. Standard manual chest

compressions have been shown to be universally superior
to alternative techniques (1-3).
In the present review pharmacotherapy in mainly two
rhythm abnormalities such as VF/VT or nonVF/VT leading
to cardiac arrest is addressed. Specific treatments for
brady- and tachyarrhythmias are outside the scope of this
article.
The reason for using vasoconstrictor agents in routine
pharmacological efforts to increase coronary perfusion
pressure is because of the insufficient release of
endogenous
vasoconstrictor
caused
by
the
neuroendocrine response to cardiac arrest. Vasopressors
routinely used in CPR can be classified as adrenergic or
nonadrenergic according to the mechanism of action (4).

Vasopressors
Vasopressor agents given during cardiac arrest aim to
improve aortic diastolic pressure. Consequently, increases
in coronary and cerebral perfusion pressures enhance
both myocardial and cerebral blood flow and improve
survival (4,5).
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Table 1.

Adrenergic vasopressors

A classification method used to define the acceptability of
methods/drugs (10).

Adrenaline (epinephrine)
Adrenergic agonist; adrenaline (epinephrine) is
routinely used to enhance cerebral and myocardial blood
flow by preventing arterial collapse and by augmenting
aortic diastolic pressure through alpha 1 and 2 receptors
(1). Its alpha adrenergic receptor stimulating properties
improves coronary perfusion pressure, while its
potentially harmful beta adrenergic effects primarily beta
1 actions (inotropic and chronotropic) result in increases
in myocardial oxygen consumption, in the incidence of
ventricular arrythmias, and intrapulmonary shunting due
to reduced hypoxic pulmonary vasoconstriction (4,5).
Accordingly adrenaline increases myocardial lactate
concentration and decreases myocardial ATP content (5).
Although beta 2 actions are predominantly
bronchodilatory, its stimulation in the myocardium
further increases oxygen consumption during CPR and
the severity of myocardial ischemic injury after successful
CPR (5).
Adrenaline has not been shown to improve outcome
(Class indeterminate) (Table 1 and 2), although it is one

Class I

Definitely helpful

Class IIa

Acceptable, probably helpful

Class IIb

Acceptable, an optional or alternative intervention

Class Indeterminate

Obscure

Class III

Not indicated, may be harmful

of the mainly used vasopressors in the practice of
advanced cardiac life support (ACLS) (Figure) (3).
Standard optimal dose recommendation for intravenous
adrenaline is 1 mg (10 ml of in 10000 solution or 1 ml
of 1 in 1000 solution) every 3-5 minutes according to
ACLS guidelines (6, 7). However, in the majority of cases
adrenaline did not appear to be administered according to
current ACLS guidelines. The median interval between
adrenaline doses during CPR was 6.5 min (7).
Additionally, adrenaline is believed to stiffen the major
vessels leading away from the heart, thus adding to the
transmission of the raised intrathoracic pressure and the
forward flow of the blood, which is known as the the
chest pump theory (6). If venous cannulation has not

Table 2. Recommendations for administration of CPR drugs.

Drug

Indication

Adrenaline
Vasopressin

Indeterminate
Alternative to adrenaline in VF/pulseless VT
refractory to three initial shocks

Amidarone

Class

IIb

Following adrenaline as early as after the third shock provided
in the treatment of shock refractory VF/pulseless VT

IIb

Lidocaine

Alternative if amiodarone is unavailable

IIb

Procainamid

Alternative if amiodarone is unavailable

IIb

Magnesium

Refractory VF if suspicion of hypomagnesemia

IIb

Sodium bicarbonate

If known preexisting hyperkalemia

I

1.If known preexisting bicarbonate-responsive acidosis
2.If overdose with tricyclic antidepressants
3. To alkalinize the urine in drug overdoses

IIa

1.If intubated and long arrest interval
2.Upon return of spontaneous circulation after long arrest interval

IIb

Respiratory acidosis

III

Calcium

Routine use

III

Atropine

Bradycardia

I?
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Figure.

Algorhythm of advanced cardiac life support including ventricular fibrillation/ventricular tachycardia (VF/VT), refractory VF/VT, pulseless
electrical activity (PEA) and asystole.

ET: Endotracheal
The 4H:
1. Hypoxia
2. Hypovolemia
3. Hyper/hypokalemia, hypocalcemia and acidemia
4. Hypothermia

The 4T:
1. Tension pneumothorax
2. Cardiac tamponade
3. Thromboembolic or mechanical obstruction (e.g.pulmonary embolism)
4. Toxic or therapeutic substances in overdose
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been achieved immediately, then adrenaline 2-3 mg
diluted in 10 ml normal saline (0.9%) may be
administered via the endotracheal (ET) route and
followed by five ventilations to aid spread throughout the
lungs (6).
Since each drug used in pediatric resuscitation has a
different dosage in mg/kg weight and a different
presentation in ml/kg in the ampule, a common dose of
0.1 ml/kg body weight has been established in order to
simplify drug use in emergency so that all the new
ampules contain the same dose (8). In children,
adrenaline can be given at a dose of 10 µg/kg or 0.1
ml/kg 1 in 10000 solution (1).
Dose dependent improvement in regional myocardial
and cerebral blood flow has been recorded in various
studies but no improvement in hospital discharge and
survival has been seen (1,6). High doses up to 0.2 mg/kg
adrenaline may further enhance coronary perfusion
pressure, but does not seem to improve long-term
survival after out of hospital or in hospital cardiac arrest
(4). On the other hand a higher dose of 0.01 to 0.1
mg/kg improved the resuscitation rate from 40% to 90%
(5). Comparison of standard and high doses of adrenaline
did not show statistically significant improvement. In
addition to the detrimental effects of beta 1 and alpha 1
actions of adrenaline, it induces disproportionate
increases in systolic pressures of the pulmonary artery,
pulmonary capillary, and pulmonary venous pressure.
Excessive increases in pulmonary capillary filtration
pressure may precipitate pulmonary edema (5).
Noradrenaline (norepinephrine)
Noradrenaline is a potent adrenergic agonist that
stimulates alpha 1 and 2 receptors with a minor beta 2
receptor activity. In contrast to adrenaline it produces
greater vasoconstriction such that total peripheral
resistance is significantly increased. Increase in both
myocardial and cerebral blood flows are comparable with
that produced by adrenaline. It also acts on beta 1
receptors and thereby increases myocardial oxygen
consumption and the risk of ischemic injury during CPR
(5).
Alpha adrenergic agonist
Activation of alpha-1 adrenergic receptors result in
increased peripheral vascular resistance and myocardial
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and cerebral perfusion pressure as well as blood flows.
Predominant alpha-1 agonists such as phenylephrine and
methoxamine, specifically increase peripheral vascular
resistance (5). However, alpha-1 adrenergic is rapidly
desentisized in the ischemic myocardium. Stimulation of
myocardial alpha-1 receptors increases both inotropic and
chronotropic responses leading to increase in myocardial
oxygen consumption and this augments global ischemic
injury (5).

Alpha-2 adrenergic agonist
Stimulation of postsynaptic alpha-2 adrenergic
receptors increases endothelial nitric oxide production
which counterbalances coronary vasoconstriction induced
by alpha-2 adrenergic stimulation. Stimulation of
presynaptic alpha-2 adrenergic receptors inhibits the
release of endogenous catecholamine, which is beneficial
because of the greater levels of endogenous
catecholamines during CPR (5). There are three subtypes
of alpha-2 receptors. Central vasodilator effects are
mediated by 2A and 2C, peripheral vasoconstrictor
effects are mediated by 2B(5).
It has beeen reported that a selective alpha-2
adrenergic agonist alpha-methyl norepinephrine without
central negative inotropic and chronotropic effects is as
effective in restorating spontaneous circulation after
untreated VF for CPR and demonstrates less
postresuscitation myocardial injury in animal studies (9).

Nonadrenergic vasopressors
Vasopressin
Vasopressin has been shown to significantly raise
coronary perfusion pressures and to increase the return
of the rate of spontaneous circulation (6). It acts on nonadrenergic V1 receptors and has been recommended in
case of fibrillatory arrest as 40 IU as an iv single dose
(Figure). It has several advantages over adrenaline in CPR
due to lack of the beta effect and impact of acidosis on its
efficacy, and lower incidence of post resuscitation
myocardial dysfunction (1).
Endogenous arginine vasopressin is called antidiuretic
hormone (ADH) and is released from the posterior
pituitary in response to increased serum osmolality or
reduced plasma volume. Under normal conditions it
regulates water balance without producing hypertension
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despite its high circulating levels. On the other hand in
shock states, its vasopressor action is greatly enhanced.
Vasopressin acts via specific renal (V-2), and vascular (V1) receptors. It produces vasoconstriction in non vital
circulations like skin, skeletal muscle, and small bowel,
thereby diverting the blood to the brain, heart, and
kidneys. The vasopressin analogue desmopressin is
mainly a V-2 agonist but has 0.4% of the pressor activity
of arginine vasopressin. Plasma half life of vasopressin is
24 min and two thirds of it is metabolized by the kidneys
(5).
According to the current CPR guidelines, use of
vasopressin as an alternative to adrenaline for shock
refractory ventricular fibrillation is recommended as a
Class IIb (Table 1, 2) (10). Use of vasopressin in patients
with asystole or pulseless electrical activity (PEA) or in
infants and children is recommended as Class
indeterminate (5). It is not established whether a second
dose of vasopressin is required or not (1).
Since vasopressin is one of the most important
endogenously released stress hormones during shock,
vasopressin and its analogs may also be useful to treat
septic and catecholamine-resistant shock and reduce
bleeding and mortality associated with esophageal
variceal hemorrhage (11,12).
It has been reported that vasopressin and adrenaline
were equally effective in CPR in the rat asphyxia model in
the short period (13). In addition to this study, it has
been shown that the triple drug therapy combination of
adrenaline, vasopressin and nitroglycerine significantly
improved both left ventricular, and cerebral perfusion
during CPR compared with adrenaline alone (14). In
another study repeated administration of combination of
vasopressin and adrenaline ensured long term survival
with full neurologic recovery in the prolonged CPR model
of pigs (15). It has been reported that spontaneous
circulation immediately returned following a single dose
(40 IU) of vasopressin in refractory cardiocirculatory
arrest to 2 mg iv adrenaline in a 19 year old female with
prolonged hypothermia after near drowning (16). This
case report showed that vasopressin could be beneficial in
restoring spontaneous circulation even during
hypothermic CPR prior to rewarming, in contrast to the
CPR guidelines of European Resuscitation Council not to
administer vasopressors to support coronary perfusion
pressure during hypothermic CPR (17).

Angiotensine II (AT-II)
Angiotensin II is approximately 40 times more potent
than norepinephrine It increases peripheral vascular
resistance via direct and indirect vasoconstrictor effects
on precapillary arterioles and postcapillary venules.
Vasoconstriction is induced by activation of AT-1
receptors on vascular smooth muscle cells. AT-II causes
release of endogenous catecholamines from the adrenal
medulla leads to peripheral vasoconstriction. Intravenous
injection of angiotensin II during CPR further increases
already increased serum concentrations of endogenous
adrenaline and noradrenaline (5).

Endothelin-1
Endothelin-1 carries potent nonadrenergically
mediated vasoconstrictor properties by increasing calcium
concentration within vascular smooth muscle cells via a
nonadrenergic pathway. It is hemodynamically more
advantageous than adrenaline because of lacking beta
adrenergic effects. The peripheral effects of endothelin
improve coronary perfusion pressure and cerebral blood
flow. Endothelin-1 levels are either normal or elevated in
human survivors of cardiac arrest during CPR. Long half
life of endothelin could result in a worsened
postresuscitation
outcome.
Therefore,
the
vasoconstrictor effect of endothelin-1 should be further
investigated in setting of cardiac arrest (5).

Antiarrythmic agents
The use of antiarrythmic drugs has been
recommended to aid electrical defibrillation, to prevent
the reoccurrence of ventricular fibrillation and to
terminate serious electrical arrythmias (6). Antiarrythmic
drugs should increase the likelihood of successful
defibrillation by suppressing a variety of potentially
malignant arrhythmias (5).

Amiodarone
Amiodarone should be considered as a Class IIb,
following adrenaline, to treat shock refractory VF/VT as
early as after three shocks are provided (3). Amiodarone
improves survival to hospital admission but not to
hospital discharge because of the side effects such as
hypotension and bradycardia (5).
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Amiodarone does prevent ventricular arrhythmias and
animal studies demonstrated that it could reduce the
defibrillation threshold (6). In an experimental model of
persistant VF, animals receiving amiodarone alone had
significantly lower resuscitation generated aortic (systolic
and diastolic), right atrial systolic and coronary perfusion
pressures than did either adrenaline alone or the
combination of amiodarone and adrenaline. This study
suggested that for optimal hemodynamic support during
ongoing CPR adrenaline or other vasoconstrictive agents
should be given in combination with, or precede, the
administration of amiodarone (18).
Amiodarone has many different hemodynamic effects.
It blocks potassium channels leading to prolongation in
the duration of the action potential. It also causes block in
sodium and calcium channels and alpha and beta
adrenergic receptors. As a result of its direct effect on
smooth muscle, and its ability to block calcium channels
and alpha adrenergic receptors, amiodarone dilates
coronary arteries. It also dilates peripheral arteries
leading to vasodilatation and reduction in afterload and
systemic blood pressure. Hypotension complicates its use
particularly in the setting of a rapid infusion. Therefore,
amiodarone is effective in treating most ventricular and
supraventricular tachyarrythmias (5).
The recommended dose of amiodarone is 300 mg
diluted in 20 ml 5% dextrose as an iv bolus via a
peripheral vein when there is no central venous route (3).
It should be given after the third shock without allowing
delay in the delivery of the fourth shock (5). A further
dose of 150 mg amiodarone may be required in
refractory cases followed by an infusion of 1 mg min-1 for
6 h and then 0.5 mg/min to a maximum of 2 g in 24 h.
However, according to European datasheet maximum
dose of amiodarone is 1.2 g in 24 h (3).
It has been reported that dogs receiving amiodarone
alone had significantly lower resuscitation generated
aortic systolic and diastolic and right atrial systolic and
coronary perfusion pressures than did either adrenaline
alone or the combination of amiodarone and adrenaline in
the persistent VF model (18).

Lidocaine
Lidocaine is a second choice after amiodarone and
procainamid. It is acceptable for use in pVT after
defibrillation, hemodynamically unstable ventricular
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premature contractions and hemodynamically stable VT
(1). Its clinical efficacy in refractory VF led to an
indeterminate Class (4). It has been used to treat
resistant VF if amidoarone is not available (3). However,
studies have shown that lidocaine offers no improvement
in survival from VF. It may actually raise the defibrillation
threshold and prevent the recurrence of VF after
successful defibrillation (6).
The recommended dose is 1-1.5 mg/kg iv bolus and is
repeated in the dose of 0.5-0.75 mg/kg not exceeding 3
mg/kg/h. Continuous infusion of 1-4 mg/min is started
only if spontaneous circulation returns during CPR (1).

Procainamide
It is an other alternative to amiodarone but the
necessity for relatively slow rate of infusion (30 mg min-1
to a total of 17 mg/kg) makes it a less favorable option
(3).

Magnesium
The antiarrhythmic action of magnesium is mediated
by the activation of membrane sodium-potassium
adenosine triphosphatase and blocking of slow calcium
channels (4). Magnesium is universally accepted for the
therapy of torsades de pointes (15). 1-2 g (4-8 mmol) of
magnesium sulphate diluted in 100 ml of 5% dextrose is
recommended to be given over 30-60 min followed by an
infusion of 0.5 -1 g/h (1). Its use is recommended for
shock refractory VF when hypomagnesemia is suspected
e.g patients on potassium losing diuretics, because
magnesium mirrors the action of extracellular potassium
in stabilizing myocardial cell membrane (1,3,4).

Others
Atropine
Atropine enhances automacticity and conduction of
both sinoatrial and atriventricular node. It is most
effective in hemodynamically significant bradycardia due
to vagal stimulation (1). The recommended dose in PEA
associated with bradycardia (<60 beat/min) and asystole
is 3 mg iv and 6 mg ET (1, 3). For the treatment of sinus
bradycardia, 0.5 mg (approximately 10 µg kg-1) iv should
be given and repeated if required up to a total dose of 40
µg kg-1 (1).
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Calcium
Despite the fact that extracellular calcium enhances
the contractile force of cardiac muscle, there is no
evidence to indicate that calcium administration during
CPR improves cardiac performance. In fact ischemia
promotes intracellular calcium accumulation, leading to
membrane disruption and uncoupling of oxidative
phosphorylation (10). Because of the risk of calcium
accumulation and subsequent cell injury during periods of
tissue ischemia, it is indicated when the patient exhibits
acute calcium channel blocker toxicity or if there is
evidence of ionized hypocalcemia or hyperkalemia. The
recommended dose of calcium gluconate is 0.5 ml kg-1
(maximum 20 ml) of a 10% solution of calcium chloride
in a dose of 0.2 ml kg-1 (maximum 10 ml) (1).

Sodium bicarbonate (NaHCO3)
Bicarbonate therapy should be considered only after
the confirmed interventions such as defibrillation, cardiac
compression, intubation, ventilation and vasopressor
therapy have been ineffective (1). The recommended
bicarbonate administration is shown in Table 2. The
bicarbonate therapy should be guided by determining the
bicarbonate concentration or calculating the base deficit
obtained from arterial blood gas analysis (1).

Conclusion
Survival following cardiac arrest mostly depends on
the interval between collapse to initiation of CPR and
collapse to defibrillation. Although no drug has been
reliably proven to increase survival to hospital discharge
after cardiac arrest, basic cardiac medication drugs used
during ACLS were reviewed. For example; vasopressin
has been recommended in case of fibrillatory arrest, the
use of lidocaine in refractory ventricular fibrillation
remains contentious, whereas amiodarone is
recommended after defibrillation and adrenaline.
Lidocaine and procainamide are alternatives if amiodarone
is not available. Amiodarone may improve short term
survival after out-of-hospital ventricular fibrillation
cardiac arrest. Magnesium therapy is recommended
especially for torsades de pointes and shock resistant
ventricular fibrillation associated with hypomagnesemia.
Atropine is the drug of choice in PEA associated with
bradycardia and asystole. Sodium bicarbonate and
calcium indications are restricted. It is still difficult to say
whether drugs used during ACLS are really effective
unless further prospective randomized human studies are
completed.
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